{"id":"multiprofen-cc-plus-standard-treatment","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_fixedAt":"2026-03-30T18:19:40.782690","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Multiprofen-CC™ appears to be a formulation combining ibuprofen or a related profen with additional components (CC likely denotes a specific combination or controlled-release formulation) designed to enhance anti-inflammatory efficacy when used alongside standard therapeutic regimens. The exact molecular mechanism and target remain proprietary to McMaster University's development program.","oneSentence":"Multiprofen-CC™ is an anti-inflammatory agent combined with standard treatment to reduce inflammation and improve clinical outcomes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:19.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(2776)"],"trialDetails":[{"nctId":"NCT06966206","phase":"PHASE3","title":"Multiprofen-CC to Reduce Pain in Hand Arthritis","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2026-01-01","conditions":"Hand Osteoarthritis","enrollment":42},{"nctId":"NCT06202989","phase":"PHASE3","title":"Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty","status":"RECRUITING","sponsor":"KAZM Pharmaceuticals Inc.","startDate":"2024-09-09","conditions":"Postsurgical Pain","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2776,"recentPublications":[{"date":"2026","pmid":"41908285","title":"A randomized controlled double-blind study on the brain protection of infantile patients with epileptic spasm syndrome through atomized inhalation of hydrogen-oxygen gas.","journal":"Frontiers in neurology"},{"date":"2026 Mar 21","pmid":"41899622","title":"On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma.","journal":"Cancers"},{"date":"2026 Mar","pmid":"41885091","title":"Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.","journal":"The Journal of international medical research"},{"date":"2026","pmid":"41883866","title":"Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.","journal":"Therapeutic advances in medical oncology"},{"date":"2026","pmid":"41873370","title":"Case Report: Rare Multidrug-Resistant Enterobacter Cloacae Complicated by Invasive Pulmonary Aspergillosis in an Elderly Patient with Advanced Lung Adenocarcinoma Treated with Osimertinib.","journal":"Infection and drug resistance"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Multiprofen-CC™ plus standard treatment","genericName":"Multiprofen-CC™ plus standard treatment","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}